Pit-1 will be immunoreactive in pituitary carcinomas of the somatotroph, lactotroph, and thyrotroph lineages while SF1 and GATA3 will be immunoreactive in the carcinomas of the gonadotroph lineage. Here, GATA3 is linked to pituitary adenocarcinoma.